A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease (aGVHD) Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant (Allo HSCT) PatientsRegimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant (Allo HSCT) Patients
-
- STATUS
- Not Recruiting
Summary
The objective of this study is to determine the maximum tolerated dose (MTD) of bortezomib in combination with cyclosporine and methotrexate as acuite graft versus host disease (aGVHD) prophylaxis in pediatric patients undergoing allogeniec hematopoietic stem cell transplant (alloHSCT).
Description
The objective of this study is to determine the maximum tolerated dose (MTD) of bortezomib in combination with cyclosporine and methotrexate as acuite graft versus host disease (aGVHD) prophylaxis in pediatric patients undergoing allogeniec hematopoietic stem cell transplant (alloHSCT).
Details
| Condition | Acute Graft Versus Host Disease |
|---|---|
| Age | 1years - 21years |
| Clinical Study Identifier | TX3769 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.